PCSK9 and Stroke: Therefore, our present and previous results (9), suggesting a role of Apo CIII in cerebral ischemic disease, may be considered as consistent with the recommendations in current therapeutic guidelines which indicate high-dose statin (e.g., atorvastatin 80 mg), if needed also associated with ezetimibe and/or PCSK9 inhibitors, to reduce the risk of stroke recurrence (18).